Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Summit Therapeutics ( (SMMT) ) has issued an announcement.
On November 7, 2025, Summit Therapeutics announced that Akeso, its partner, published results from the Phase III HARMONi-A trial conducted in China. The trial demonstrated that ivonescimab combined with platinum-doublet chemotherapy significantly improved overall survival in patients with EGFR-mutated non-small cell lung cancer compared to chemotherapy alone. The study, which was the first Phase III trial for ivonescimab, showed a median overall survival of 16.8 months versus 14.1 months for chemotherapy alone, achieving a hazard ratio of 0.74. This result highlights ivonescimab’s potential to address high unmet medical needs in cancer treatment, offering a favorable risk-benefit profile and demonstrating efficacy where other PD-1 therapies have not succeeded.
The most recent analyst rating on (SMMT) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Summit Therapeutics stock, see the SMMT Stock Forecast page.
Spark’s Take on SMMT Stock
According to Spark, TipRanks’ AI Analyst, SMMT is a Neutral.
Summit Therapeutics’ stock score reflects significant financial challenges, including lack of revenue and ongoing losses, balanced by a strong equity position. Technical indicators show positive momentum, supporting short-term interest. Valuation remains weak due to negative earnings and no dividend. Positive clinical developments from the earnings call bolster the score, highlighting potential for future growth.
To see Spark’s full report on SMMT stock, click here.
More about Summit Therapeutics
Summit Therapeutics Inc. operates in the biopharmaceutical industry, focusing on developing novel therapies for unmet medical needs. The company collaborates with partners like Akeso, Inc. to advance its pipeline, particularly in oncology, with products such as ivonescimab, a bispecific antibody targeting cancer treatment.
Average Trading Volume: 4,136,743
Technical Sentiment Signal: Hold
Current Market Cap: $13.45B
For a thorough assessment of SMMT stock, go to TipRanks’ Stock Analysis page.